Alexion Pharmaceuticals Inc (ALXN) Posts Q3 EPS of $0.29, Beats By 8c; Guides
ALXN Hot Sheet
EPS Growth %: -23.7%Financial Fact:
Cost of sales: 28.27M
Today's EPS Names:
TARO, BRLI, TLB, More
Alexion Pharmaceuticals Inc (NYSE: ALXN) reports Q3 EPS of $0.29, 8 cents better than the analyst estimate of $0.21. Revenue for the quarter was $102.63 million, which compares to the estimate of $98.03 million.
Sees FY09 non-GAAP EPS of $1.15 - $1.18, from $1.01 - $1.05.
Sees FY09 non-GAAP EPS of $1.15 - $1.18, from $1.01 - $1.05.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Tiffany & Co. (TIF) Misses Q1 EPS Views; Lowers FY12 EPS, Revs Growth Outlook
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
